116 related articles for article (PubMed ID: 26808665)
21. TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.
Castoldi R; Schanzer J; Panke C; Jucknischke U; Neubert NJ; Croasdale R; Scheuer W; Auer J; Klein C; Niederfellner G; Kobold S; Sustmann C
Protein Eng Des Sel; 2016 Oct; 29(10):467-475. PubMed ID: 27578890
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
23. Receptor tyrosine kinases: principles and functions in glioma invasion.
Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada J
Adv Exp Med Biol; 2013; 986():143-70. PubMed ID: 22879068
[TBL] [Abstract][Full Text] [Related]
24. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
25. AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer.
Jhaveri TZ; Woo J; Shang X; Park BH; Gabrielson E
Oncotarget; 2015 Jun; 6(17):14754-65. PubMed ID: 26143491
[TBL] [Abstract][Full Text] [Related]
26. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
27. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
28. Two-Pulse Endosomal Stimulation of Receptor Tyrosine Kinases Induces Cell Proliferation.
Pennock S; Billing S; Wang Z; Wang Y
Methods Mol Biol; 2017; 1652():127-133. PubMed ID: 28791639
[TBL] [Abstract][Full Text] [Related]
29. Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion.
Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada JI
Adv Exp Med Biol; 2020; 1202():151-178. PubMed ID: 32034713
[TBL] [Abstract][Full Text] [Related]
30. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
31. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition.
Burtness B; Bauman JE; Galloway T
Lancet Oncol; 2013 Jul; 14(8):e302-9. PubMed ID: 23816296
[TBL] [Abstract][Full Text] [Related]
32. Effector mechanisms of therapeutic antibodies against ErbB receptors.
Peipp M; Dechant M; Valerius T
Curr Opin Immunol; 2008 Aug; 20(4):436-43. PubMed ID: 18585454
[TBL] [Abstract][Full Text] [Related]
33. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
[TBL] [Abstract][Full Text] [Related]
34. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
35. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
Ahmad N; Gali H; Javed S; Agarwal R
Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
[TBL] [Abstract][Full Text] [Related]
36. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
37. Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.
Fauvel B; Yasri A
MAbs; 2014; 6(4):838-51. PubMed ID: 24859229
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
39. JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies.
Manole S; Richards EJ; Meyer AS
Cancer Res; 2016 Sep; 76(18):5219-28. PubMed ID: 27450453
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
